ASH: Roche un­corks eye­pop­ping re­spons­es in bis­pe­cif­ic test, hop­ing to add a jew­el to its fu­ture port­fo­lio

In a heat­ed race with some of phar­ma’s biggest play­ers, Roche’s Genen­tech is look­ing to dri­ve a lead bis­pe­cif­ic an­ti­body pro­gram through the clin­ic against stub­born blood can­cers. As the field watch­es close­ly, Roche is now trot­ting out da­ta it thinks could earn its drug a first shot at the mar­ket.

Roche’s mo­sune­tuzum­ab, a bis­pe­cif­ic tar­get­ing the CD20 pro­tein on the sur­face of tu­mors and the CD3 pro­tein on T cells, post­ed a 60% com­plete re­sponse rate, ac­cord­ing to da­ta from near­ly 100 pa­tients with third-line-or-lat­er fol­lic­u­lar lym­phoma in an open-la­bel, sin­gle-arm Phase I/II study dubbed GO29781 pre­sent­ed Sat­ur­day at #ASH21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER